Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04291560
Other study ID # 18-3091
Secondary ID 1R01NR017944-01A
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date March 1, 2020
Est. completion date July 1, 2025

Study information

Verified date May 2024
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to determine whether a stretching intervention is superior to a usual care control condition (moderate/vigorous activity 30 minutes daily, 5 days per week) for pregnant women from 27 to 37 gestational weeks.


Description:

Although being sedentary can lead to excess risk for maternal and child mortality and morbidity, most pregnant women reduce their physical activity and only 8% meet the recommendations in the 3rd trimester. In a prior randomized control trial, it was found that fewer women who stretched developed preeclampsia than did women who walked (3/60 "stretchers" vs. 10/64 "walkers", p=.05). In this study, participants will either receive a stretching intervention


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 306
Est. completion date July 1, 2025
Est. primary completion date May 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pregnant at less than 24 weeks gestation - Singleton pregnancy - BMI = 30 kg/m^2 at their first prenatal care visit - English or Spanish speaking Exclusion Criteria: - Women who expect or are scheduled to deliver prior to 37 weeks gestation - Women who expect to move from the area during their participation in the study - Women who are unable to exercise for 30 or more minutes 3 times per week

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Stretching Exercise Intervention
Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.

Locations

Country Name City State
United States The University of North Carolina at Chapel Hill Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill National Institute of Nursing Research (NINR)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in systolic blood pressure from baseline (27 gestational weeks) to 32 gestational weeks Average systolic blood pressure measurement between two measurements, assessed at baseline (27 gestational weeks) and 32 gestational weeks. Three total measurements will be taken, the first will be removed and the second two averaged. Baseline to 32 gestational weeks
Primary Change in systolic blood pressure from baseline (27 gestational weeks) to 37 gestational weeks Average systolic blood pressure measurement between two measurements, assessed at baseline (27 gestational weeks) and 37 gestational weeks. Three total measurements will be taken, the first will be removed and the second two averaged. Baseline to 37 gestational weeks
Primary Change in diastolic blood pressure from baseline (27 gestational weeks) to 32 gestational weeks Average diastolic blood pressure measurement between two measurements, assessed at baseline (27 gestational weeks) and 32 gestational weeks. Three total measurements will be taken, the first will be removed and the second two averaged. Baseline to 32 gestational weeks
Primary Change in diastolic blood pressure from baseline (27 gestational weeks) to 37 gestational weeks Average diastolic blood pressure measurement between two measurements, assessed at baseline (27 gestational weeks) and 37 gestational weeks. Three total measurements will be taken, the first will be removed and the second two averaged. Baseline to 37 gestational weeks
Primary Change in sympatho-vagal balance projection period (PEP) for sympathetic activity from baseline (27 gestational weeks) to 32 gestational weeks he time in milliseconds from the ECG R point (left ventricular depolarization) and the B-point on the Dz/dt wave form (opening of the aortic valve), assessed at baseline (27 gestational weeks) and 32 gestational weeks. Baseline to 32 gestational weeks
Primary Change in sympatho-vagal balance projection period (PEP) for sympathetic from baseline (27 gestational weeks) to 37 gestational weeks The time in milliseconds from the ECG R point (left ventricular depolarization) and the B-point on the Dz/dt wave form (opening of the aortic valve), assessed at baseline (27 gestational weeks) and 37 gestational weeks. Baseline to 37 gestational weeks
Primary Change in high frequency of heart rate variability from baseline (27 gestational weeks) to 32 gestational weeks High frequency of heart rate variability (reported in absolute value, m^2/Hz) from an electrocardiogram, assessed at baseline (27 gestational weeks) and 32 gestational weeks. Baseline to 32 gestational weeks
Primary Change in high frequency of heart rate variability from baseline (27 gestational weeks) to 37 gestational weeks High frequency of heart rate variability (reported in absolute value, m^2/Hz) from an electrocardiogram, assessed at baseline (27 gestational weeks) and 37 gestational weeks. Baseline to 37 gestational weeks
Primary Change in arterial stiffness assessed by SphygmoCor XCEL from baseline (27 gestational weeks) to 32 gestational weeks Carotid-femoral pulse wave velocity is a measure of arterial stiffness reported in m/s. Lower values reflect less arterial stiffness. Baseline to 32 gestational weeks
Primary Change in arterial stiffness assessed by SphygmoCor XCEL from baseline (27 gestational weeks) to 37 gestational weeks Carotid-femoral pulse wave velocity is a measure of arterial stiffness reported in m/s. Lower values reflect less arterial stiffness. Baseline to 37 gestational weeks
Secondary Onset of preeclampsia anytime between baseline (27 weeks gestation) and the end of pregnancy Presence of preeclampsia anytime between baseline (27 weeks gestation) and the end of pregnancy in the electronic medical record. From baseline (27 weeks gestation) through delivery
Secondary Onset of eclampsia anytime between baseline (27 weeks gestation) and the end of pregnancy Presence of eclampsia anytime between baseline (27 weeks gestation) and the end of pregnancy in the electronic medical record. From baseline (27 weeks gestation) through delivery
Secondary Onset of pregnancy induced hypertension anytime between baseline (27 weeks gestation) and the end of pregnancy Presence of pregnancy induced hypertension anytime between baseline (27 weeks gestation) and the end of pregnancy in the electronic medical record. From baseline (27 weeks gestation) through delivery
Secondary Onset of gestational diabetes anytime between baseline (27 weeks) and the end of pregnancy Presence of gestational diabetes anytime between baseline (27 weeks gestation) and the end of pregnancy in the electronic medical record. From baseline (27 weeks gestation) through delivery
Secondary Preterm delivery at end of pregnancy Presence of preterm delivery in the electronic medical record. From baseline (27 weeks gestation) through delivery
Secondary Elective or emergency cesarean section at end of pregnancy Presence of an elective or emergency cesarean section in the electronic medical record. From baseline (27 weeks gestation) through delivery
Secondary Composite score of Maternal Outcomes at the End of Pregnancy. The composite score of maternal outcomes (onset of preeclampsia, eclampsia pregnancy induced hypertension, gestational diabetes, preterm delivery, and elective or emergency cesarean section) is obtained at the end of pregnancy. Scores range from 0-6, with higher scores indicating a less healthy pregnancy. From baseline (27 weeks gestation) through delivery
Secondary Intrauterine death at end of pregnancy Presence of an intrauterine death in the electronic medical record. From baseline (27 weeks gestation) through delivery
Secondary Child being small for gestational age at the end of pregnancy Presence of the child being small for gestational age in the electronic medical record. From baseline (27 weeks gestation) through delivery
Secondary Child being large for gestational age at the end of pregnancy Presence of the child being large for gestational age in the electronic medical record. From baseline (27 weeks gestation) through delivery
Secondary Neonatal intensive care unit admission at the end of pregnancy Presence of a neonatal intensive care unit admission in the electronic medical record. From baseline (27 weeks gestation) through delivery
Secondary Composite Score of Fetal/Neonatal Outcomes at the End of Pregnancy. The composite score of fetal/neonatal outcomes (intrauterine death, child being small, child being large, neonatal intensive care admission) is obtained at the end of pregnancy. Scores range from 0-4, with higher scores indicating a less healthy fetus/neonate. From baseline (27 weeks gestation) through delivery
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2